Financial Performance - For the nine months ended December 31, 2020, the group's revenue was HKD 45,745,000, a decrease of 8.1% compared to HKD 49,249,000 for the same period in 2019[7]. - Gross profit for the nine months was HKD 25,169,000, representing a slight decrease of 2.1% from HKD 25,711,000 in the previous year[7]. - The net profit attributable to the owners of the company for the nine months was HKD 7,729,000, down 2.3% from HKD 7,914,000 in the same period last year[7]. - Basic earnings per share for the nine months was HKD 0.97, compared to HKD 0.99 for the same period in 2019[7]. - Total comprehensive income for the three months ended December 31, 2020, was HKD 2,035,000, down from HKD 3,331,000 in the same period of 2019, a decrease of 38.9%[7]. - The group reported a profit attributable to owners of the company of HKD 7,729,000 for the nine months ended December 31, 2020, a decrease from HKD 7,914,000 in the previous year[47]. - The company recorded a profit of approximately HKD 7,700,000 for the nine months ended December 31, 2020, down from HKD 7,900,000 in the same period of 2019[65]. Revenue and Expenses - The group incurred administrative and other operating expenses of HKD 17,038,000 for the nine months, an increase of 8.1% from HKD 15,754,000 in the previous year[7]. - Financial costs for the nine months were HKD 70,000, down from HKD 149,000 in the previous year, a decrease of 53.0%[7]. - The group incurred research and development expenses of approximately HKD 363,000 for the nine months ended December 31, 2020, compared to HKD 432,000 in the same period of 2019[36]. - Administrative and other operating expenses increased by approximately HKD 1,200,000 or 8.2% to about HKD 17,000,000 for the nine months ended December 31, 2020, primarily due to an increase in the workforce[59]. Revenue Trends - The group reported a revenue of HKD 15,100,000 for the three months ended December 31, 2020, a decrease of 12.5% compared to HKD 17,248,000 in the same period of 2019[26]. - For the nine months ended December 31, 2020, the revenue was HKD 45,745,000, down 7.6% from HKD 49,249,000 in the previous year[26]. - Revenue from a major customer amounted to HKD 5,459,000, representing over 10% of the group's total revenue for the nine months ended December 31, 2020[27]. - The company's revenue decreased by approximately 7.1% from about HKD 49,200,000 in the nine months ended December 31, 2019, to about HKD 45,700,000 in the nine months ended December 31, 2020[57]. Dividends and Shareholder Information - The group did not declare an interim dividend for the nine months ended December 31, 2020, consistent with the previous year[41]. - The company did not declare an interim dividend for the nine months ended December 31, 2020[66]. - As of December 31, 2020, B&A Success holds 557,424,000 shares, representing 69.68% of the company's total equity[77]. - The company has a stock option plan that allows for the issuance of up to 80,000,000 shares, which is 10% of the total shares issued at the time of listing[78]. - At the end of the reporting period, a total of 71,940,000 shares are available for issuance under the stock option plan, accounting for 8.99% of the company's total issued share capital[81]. - No shares were purchased, sold, or redeemed by the company or its subsidiaries during the nine months ending December 31, 2020[87]. Market and Strategic Outlook - The company has not announced any new products or technologies during this reporting period[14]. - There are no significant market expansion or acquisition strategies mentioned in the report[14]. - The company is supplying Hong Kong's first pharmacy automation system, which is expected to address healthcare labor shortages and instill confidence in potential clients[54]. - The company plans to further expand its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[54]. - The economic impact of COVID-19 has significantly affected customer spending plans, leading to challenges for the company's clients[54]. - The company remains optimistic about the healthcare sector's prospects due to the growing elderly population and increasing medical awareness among Hong Kong citizens[54]. - The company continues to monitor the developments of COVID-19 and its potential impact on financial performance[51]. Compliance and Audit - The audit committee has reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2020, and confirmed compliance with applicable accounting standards and GEM listing rules[96]. - The group’s total non-current assets are primarily located in Hong Kong, with all revenue generated from this region[24]. - The group has only one operating segment as per the Hong Kong Financial Reporting Standards, focusing on the supply of medical instruments and related solutions[23]. - The group’s interest expenses on lease liabilities were HKD 70,000 for the nine months ended December 31, 2020, down from HKD 149,000 in the previous year[33]. - The group’s bank interest income decreased to HKD (346,000) for the nine months ended December 31, 2020, compared to HKD (693,000) in the same period of 2019[36]. - Gross profit for the nine months ended December 31, 2020, was approximately HKD 25,200,000, compared to HKD 25,700,000 for the same period in 2019, with the gross profit margin increasing from 52.2% to 55.0%[58].
君百延集团(08372) - 2021 Q3 - 季度财报